Paper39484162
Cancer metabolic reprogramming and precision medicine-current perspective.
Gao T and 4 others. Front Pharmacol, 2024. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Cancer metabolic reprogramming and precision medicine-current perspective. Papers, record 39484162. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39484162
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References69
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38430694 | Cancer energy reprogramming and the immune responses. | Cytokine | 2024 | https://conductscience.org/library/papers/38430694 | PubMed |
| 2 | 37203277 | Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib. | Adv Sci (Weinh) | 2023 | https://conductscience.org/library/papers/37203277 | PubMed |
| 3 | 38486026 | Genetic and molecular characterization of metabolic pathway-based clusters in esophageal squamous cell carcinoma. | Sci Rep | 2024 | https://conductscience.org/library/papers/38486026 | PubMed |
| 4 | 38540735 | The Role of MUC1 in Renal Cell Carcinoma. | Biomolecules | 2024 | https://conductscience.org/library/papers/38540735 | PubMed |
| 5 | 36793241 | SLC3A2 promotes tumor-associated macrophage polarization through metabolic reprogramming in lung cancer. | Cancer Sci | 2023 | https://conductscience.org/library/papers/36793241 | PubMed |
| 6 | 36860371 | Identification and characterization of a novel molecular classification incorporating oxidative stress and metabolism-related genes for stomach adenocarcinoma in the framework of predictive, preventive, and personalized medicine. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/36860371 | PubMed |
| 7 | 38627967 | Switch of ELF3 and ATF4 transcriptional axis programs the amino acid insufficiency-linked epithelial-to-mesenchymal transition. | Mol Ther | 2024 | https://conductscience.org/library/papers/38627967 | PubMed |
| 8 | 38200551 | Aberrant R-loop-mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis. | Mol Cancer | 2024 | https://conductscience.org/library/papers/38200551 | PubMed |
| 9 | 38218970 | USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/38218970 | PubMed |
| 10 | 37370109 | Epigenetic reprogramming-induced guanidinoacetic acid synthesis promotes pancreatic cancer metastasis and transcription-activating histone modifications. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37370109 | PubMed |
| 11 | 37441073 | Platelet-derived microparticles provoke chronic lymphocytic leukemia malignancy through metabolic reprogramming. | Front Immunol | 2023 | https://conductscience.org/library/papers/37441073 | PubMed |
| 12 | 37064872 | The role of lipid metabolic reprogramming in tumor microenvironment. | Theranostics | 2023 | https://conductscience.org/library/papers/37064872 | PubMed |
| 13 | 37226933 | The inhibition of Aurora A kinase regulates phospholipid remodeling by upregulating LPCAT1 in glioblastoma. | Neoplasma | 2023 | https://conductscience.org/library/papers/37226933 | PubMed |
| 14 | 37664033 | Pyrimidine metabolism regulator-mediated molecular subtypes display tumor microenvironmental hallmarks and assist precision treatment in bladder cancer. | Front Oncol | 2023 | https://conductscience.org/library/papers/37664033 | PubMed |
| 15 | 38317509 | PHGDH knockdown increases sensitivity to SR1, an aryl hydrocarbon receptor antagonist, in colorectal cancer by activating the autophagy pathway. | FEBS J | 2024 | https://conductscience.org/library/papers/38317509 | PubMed |
| 16 | 38420794 | Metabolic Landscape of Osteosarcoma: Reprogramming of Lactic Acid Metabolism and Metabolic Communication. | Front Biosci (Landmark Ed) | 2024 | https://conductscience.org/library/papers/38420794 | PubMed |
| 17 | 37161350 | The role of noncoding RNAs in metabolic reprogramming of cancer cells. | Cell Mol Biol Lett | 2023 | https://conductscience.org/library/papers/37161350 | PubMed |
| 18 | 38171333 | Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer. | Cell Metab | 2024 | https://conductscience.org/library/papers/38171333 | PubMed |
| 19 | 37012319 | Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37012319 | PubMed |
| 20 | 38040418 | Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/38040418 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42733429 | Metabolic reprogramming-mediated therapeutic resistance in renal cell carcinoma: Mechanisms and targeted intervention strategies. | iScience | 2026 | https://conductscience.org/library/papers/42733429 | PubMed |
| 42639042 | Context-dependent roles of UCP2 in cancer: functional heterogeneity, molecular mechanisms and translational perspectives. | Front Oncol | 2026 | https://conductscience.org/library/papers/42639042 | PubMed |
| 42144529 | Clinical Trials and Translational Advances in Metabolic Targeting. | Cancer Treat Res | 2026 | https://conductscience.org/library/papers/42144529 | PubMed |
| 42082463 | Multi-omics reveals CXCR4 drives immune escape in colorectal cancer via metabolic reprogramming and immune microenvironment remodeling. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42082463 | PubMed |
| 41367907 | Decoding metabolic dysfunction in cancer: foundations for early detection and personalized therapeutics. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41367907 | PubMed |
| 40723225 | Metabolic Adaptations in Cancer Progression: Optimization Strategies and Therapeutic Targets. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40723225 | PubMed |
| 40386617 | The highly expressed GOLPH3 in colorectal cancer cells activates smoothened to drive glycolysis and promote cancer cell growth and radiotherapy resistance. | J Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/40386617 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39484162
GET https://conductscience.org/api/papers/v1/39484162/references?page=2